Walleye Capital
CKPT

Walleye Capital’s Checkpoint Therapeutics CKPT Stock Holding History

Walleye Capital’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-44,500
Closed -$142K – 4348
2024
Q4 		$142K Sell
44,500
-21,448
-33% -$72.7K ﹤0.01% 3957
2024
Q3 		$148K Buy
+65,948
New +$152K ﹤0.01% 4202
2021
Q4 		– Sell
-1,653
Closed -$55 – 2131
2021
Q3 		$55 Buy
+1,653
New +$48.9K ﹤0.01% 1385

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Walleye Capital's CKPT Position: Q1 2025 in Review

Walleye Capital sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 44,500 shares — an estimated $142K sold.

Walleye Capital first reported a position in CKPT in Q3 2021 and held it in 3 quarters. The position peaked at $148K in Q3 2024. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • Walleye Capital reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 44,500 Checkpoint Therapeutics shares in Q1 2025, an estimated $142K.
  • Walleye Capital first reported a position in Checkpoint Therapeutics in Q3 2021 and held it in 3 quarters.
  • Walleye Capital's Checkpoint Therapeutics position peaked at $148K in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.